|
rs25489
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
Our findings demonstrated that the genetic variant Arg280His in XRCC1 may contribute to cancer progression and that XRCC1 Arg194Trp variants may act as a favorable prognostic indicator of resected GC, particularly among the diffuse-type GC.
|
23425027 |
2013 |
|
rs1799782
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
Our findings demonstrated that the genetic variant Arg280His in XRCC1 may contribute to cancer progression and that XRCC1 Arg194Trp variants may act as a favorable prognostic indicator of resected GC, particularly among the diffuse-type GC.
|
23425027 |
2013 |
|
rs1443465532
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
These results demonstrate that P125A endostatin inhibits the angiogenic switch during mammary gland adenocarcinoma tumor progression in the C3(1)/Tag transgenic model.
|
12209972 |
2002 |
|
rs762846821
|
|
Tumor Progression
|
|
0.020 |
GeneticVariation
|
BEFREE |
The concomitant expression of oncogenic Kras(G12D) and mutant p53 (Trp53(R172H)) in the murine pancreas results in metastatic PDA that recapitulates the cognate features of human pancreatic cancer providing an excellent animal model to identify genes required for tumor progression.
|
22158044 |
2012 |
|
rs762846821
|
|
Tumor Progression
|
|
0.020 |
GeneticVariation
|
BEFREE |
We crossed IL-6(-/-) mice with Kras(G12D) mutant mice, which develop lung tumors after activation of mutant Kras(G12D), to investigate whether IL-6 inhibition contributes to tumor progression and survival time in vivo.
|
24260500 |
2013 |
|
rs587782529
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
Thus, the R337C mutant retains some functional activity yet leads to a predisposition to cancer, suggesting that even partial inactivation of p53 oligomerization is sufficient for accelerated tumour progression.
|
9704931 |
1998 |
|
rs587782148
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
Sequencing of margins with dysplasia demonstrated an identical nonconservative mitochondrial mutation (A76T in ND4L) as the tumor, suggesting a role of mtDNA mutation in tumor progression.
|
17456604 |
2007 |
|
rs375874539
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
Our data showed that (1) the frequency of C609T NQO1 was significantly increased in TNM stage III HCC patients; (2) no significant association was found between p53 expression and C609T polymorphism of NQO1 gene; and (3) a tumor/non-tumor (T/N) ratio > 1.27 of NQO1 expression revealed by real-time qPCR analyses was positively correlated with poorer survival in patients with tumors >5 cm, suggesting that an increase of NQO1 expression may be an indicator of advanced tumor progression.
|
19688691 |
2009 |
|
rs28934578
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
Gain-of-function p53 mutants such as p53-R175H form stable aggregates that accumulate in cells and play important roles in cancer progression.
|
29593334 |
2018 |
|
rs1288373809
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
Our data showed that (1) the frequency of C609T NQO1 was significantly increased in TNM stage III HCC patients; (2) no significant association was found between p53 expression and C609T polymorphism of NQO1 gene; and (3) a tumor/non-tumor (T/N) ratio > 1.27 of NQO1 expression revealed by real-time qPCR analyses was positively correlated with poorer survival in patients with tumors >5 cm, suggesting that an increase of NQO1 expression may be an indicator of advanced tumor progression.
|
19688691 |
2009 |
|
rs4986791
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
Caco-2 cells that expressed TLR4-D299G underwent the epithelial-mesenchymal transition and morphologic changes associated with tumor progression, whereas cells that expressed wild-type TLR4 or TLR4-T399I did not.
|
21920464 |
2011 |
|
rs4986790
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
TLR4-D299G induces features of neoplastic progression in intestinal epithelial Caco-2 cells and associates with aggressive colon cancer in humans, implying a novel link between aberrant innate immunity and colonic cancerogenesis.
|
21920464 |
2011 |
|
rs1800470
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
The C allele of the Leu10Pro polymorphism may predispose men to a more rapid cancer progression.
|
18058470 |
2007 |
|
rs9282861
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
Accumulating data indicates that the polymorphism rs9282861 (R213H) is responsible for inefficient enzymatic activity and associated with cancer progression.
|
31835852 |
2019 |
|
rs1042028
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
Accumulating data indicates that the polymorphism rs9282861 (R213H) is responsible for inefficient enzymatic activity and associated with cancer progression.
|
31835852 |
2019 |
|
rs4880
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
The current data, based on a large cohort (n = 929) of Chinese patients with gastric cancer, suggested that the presence of SOD2 rs4880 and GSTP1 rs1695 genotypes may contribute to cancer progression as well as tumor aggressiveness.
|
22517484 |
2012 |
|
rs762807774
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
Mutated MITF-E87R in Melanoma Enhances Tumor Progression via S100A4.
|
29679610 |
2018 |
|
rs121918464
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
The E76K GOF mutation is the most common and active SHP2 mutation; however, the pathogenic effects and function of this mutation in CRC tumor progression have not been well characterized.
|
29323748 |
2018 |
|
rs562015640
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
The E76K GOF mutation is the most common and active SHP2 mutation; however, the pathogenic effects and function of this mutation in CRC tumor progression have not been well characterized.
|
29323748 |
2018 |
|
rs1800206
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
Frequent occurrence of advanced disease in patients with L162V polymorphism suggests a role for this polymorphism in tumor progression.
|
19119483 |
2008 |
|
rs3136797
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
We performed a case-control study to test the association between two polymorphisms in the polbeta gene: a Pro --> Arg change at codon 242 (the Pro242Arg polymorphism) and a Lys --> Met change at codon 289 (the Lys289Met polymorphism) and breast cancer risk and cancer progression.
|
17131038 |
2007 |
|
rs1273593548
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
To determine which KRAS effectors were responsible for tumor progression, we created four effector domain mutants (S35, G37, E38 and C40) in G12V-activated KRAS and expressed these alone or with BrafV600E in mouse lungs...
|
24489653 |
2014 |
|
rs752021744
|
|
Tumor Progression
|
|
0.020 |
GeneticVariation
|
BEFREE |
Additionally, we tested efficacy of PD-0325901 in Kras(G12D-LSL) conditional GEMMs (genetically engineered mouse models) which are a valuable tool in translational research to study tumor progression.
|
22684718 |
2012 |
|
rs752021744
|
|
Tumor Progression
|
|
0.020 |
GeneticVariation
|
BEFREE |
We hypothesized that tumor progression was because of concomitant activation of the mitogen-activated protein kinase pathway downstream of Kras(G12D) expression promoting cell survival and that the therapeutic effect of PF-04691502 would be enhanced by combinatory inhibition of MEK using PD-0325901.
|
21632463 |
2011 |
|
rs121913279
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
The results suggest PIK3CA H1047R mutant cells have a selective advantage in breast, contribute to breast cancer susceptibility, and drive tumor progression during breast carcinogenesis, even when present as only a subpopulation of tumor cells.
|
27108388 |
2016 |